Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ( ...

Bullish option flow detected in Iovance Biotherapeutics (IOVA) with 9,622 calls trading, 2x expected, and implied vol increasing almost 27 ...

A Philadelphia biotechnology company founded seven years ago by two former Johnson & Johnson executives has a new leader.

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company's announcement of Dan Kirby as Chief Commercial Officer.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a research report issued on Monday,Benzinga reports. Other equities ...

SG Americas Securities LLC purchased a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) in ...

I would like to extend a warm welcome to Dan Kirby on behalf of the entire Iovance team,” stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of Iovance.